Latest On Krystal Biotech, Inc (KRYS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 18:45 EST | News | Option Care, Amedisys in pact to offer Krystal Biotech’s skin disorder therapy | N/A |  |
| 2023-05-22 09:22 EST | News | Krystal Biotech announces $160M private placement | N/A | |
| 2023-05-20 02:04 EST | News | Krystal gains FDA nod for topical gene therapy for rare skin disorder | N/A | |
| 2023-05-18 22:05 EST | News | Krystal Biotech: A Promising Gene Therapy Innovator | N/A | |
| 2023-05-09 01:31 EST | News | Krystal Biotech: 2 Potential Regulatory Approvals To Carry It Forward | N/A | |
About Krystal Biotech, Inc (KRYS):
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditi read more...ons, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
General
- Name Krystal Biotech, Inc
- Symbol KRYS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 75
- Fiscal Year EndDecember
- IPO Date2017-09-20
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.krystalbio.com
Valuation
- Price/Book (Most Recent Quarter) 5.68
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$3.17
- Next Year EPS Estimate -$3.02
- Next Quarter EPS Estimate -$0.66
- Return on Assets -8%
- Return on Equity -13%
- Earnings Per Share -$1.20
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 1.77 billion
- EBITDA -17369000
- Analyst Target Price $96.1
- Book Value Per Share $14.82
Share Statistics
- Shares Outstanding 22.18 million
- Shares Float 15.42 million
- % Held by Insiders 2746%
- % Held by Institutions 74.21%
- Shares Short 1.19 million
- Shares Short Prior Month 1.08 million
- Short Ratio 5.94
- Short % of Float 7%
- Short % of Shares Outstanding 5%
Technicals
- Beta 1.18
- 52 Week High $87.29
- 52 Week Low $34.61
- 50 Day Moving Average 75.17
- 200 Day Moving Average 57.5
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Krystal Biotech, Inc (KRYS) Dividend Calendar:
Krystal Biotech, Inc (KRYS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Krystal Biotech, Inc (KRYS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Krystal Biotech, Inc (KRYS) Chart:
Krystal Biotech, Inc (KRYS) News:
Below you will find a list of latest news for Krystal Biotech, Inc (KRYS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Krystal Biotech, Inc (KRYS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest KRYS Trades:
Krystal Biotech, Inc (KRYS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-01 | 8-K (Current report) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-01 | 8-K (Current report) | |
| 2020-05-21 | 8-K (Current report) | |
| 2020-05-19 | 424B2 (Prospectus [Rule 424(b)(2)]) | |
| 2020-05-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-18 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-05-14 | 8-K (Current report) | |
| 2020-05-13 | 8-K (Current report) | |
| 2020-05-08 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-05-05 | 8-K (Current report) | |
| 2020-05-04 | 8-K (Current report) | |
| 2020-05-04 | S-3ASR (Automatic shelf registration statement of securities of well-known seasoned issuers) | |
Krystal Biotech, Inc (KRYS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Krystal Biotech, Inc (KRYS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2746%
Institutional Ownership: 7421%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-17 | Suma Krishnan | Chief Operating Officer | Sell | 1,126.00 | 47.29 | 53,248.31 | 1,836,064.00 | |
| 2020-09-17 | Suma Krishnan | Chief Operating Officer | Sell | 7,437.00 | 46.63 | 346,813.34 | 1,837,190.00 | |
| 2020-09-17 | Suma Krishnan | Chief Operating Officer | Sell | 10,594.00 | 46.09 | 488,296.53 | 1,844,627.00 | |
| 2020-09-16 | Suma Krishnan | Chief Operating Officer | Sell | 5,142.00 | 46.85 | 240,895.50 | 1,855,221.00 | |
| 2020-09-16 | Suma Krishnan | Chief Operating Officer | Sell | 9,749.00 | 46.24 | 450,821.06 | 1,860,363.00 | |
| 2020-09-15 | Suma Krishnan | Chief Operating Officer | Sell | 1,517.00 | 47.15 | 71,523.21 | 1,870,112.00 | |
| 2020-09-15 | Suma Krishnan | Chief Operating Officer | Sell | 14,435.00 | 46.21 | 667,031.25 | 1,871,629.00 | |
| 2020-06-15 | Suma Krishnan | Chief Operating Officer | Sell | 11,719.00 | 45.07 | 528,182.36 | 1,886,064.00 | |
| 2020-06-15 | Suma Krishnan | Chief Operating Officer | Sell | 11,311.00 | 44.56 | 504,057.75 | 1,897,783.00 | |
| 2020-06-15 | Suma Krishnan | Chief Operating Officer | Sell | 10,740.00 | 43.21 | 464,070.03 | 1,909,094.00 | |
| 2020-06-15 | Suma Krishnan | Chief Operating Officer | Sell | 8,652.00 | 42.24 | 365,426.74 | 1,919,834.00 | |
| 2020-06-15 | Suma Krishnan | Chief Operating Officer | Sell | 7,578.00 | 41.31 | 313,038.09 | 1,928,486.00 | |
| 2020-05-18 | Krish S Krishnan | President and CEO | Sell | 6,301.00 | 59.73 | 376,344.87 | 1,886,462.00 | |
| 2020-05-18 | Krish S Krishnan | President and CEO | Sell | 1,805.00 | 59.11 | 106,698.97 | 1,892,763.00 | |
| 2020-05-18 | Krish S Krishnan | President and CEO | Sell | 5,371.00 | 57.63 | 309,531.80 | 1,894,568.00 | |
| 2020-05-18 | Krish S Krishnan | President and CEO | Sell | 6,784.00 | 56.84 | 385,588.99 | 1,899,939.00 | |
| 2020-05-18 | Krish S Krishnan | President and CEO | Sell | 2,900.00 | 55.99 | 162,356.50 | 1,906,723.00 | |
| 2020-05-15 | Krish S Krishnan | President and CEO | Sell | 10,552.00 | 59.03 | 622,874.01 | 1,909,623.00 | |
| 2020-05-15 | Krish S Krishnan | President and CEO | Sell | 12,445.00 | 58.09 | 722,872.80 | 1,920,175.00 | |
| 2020-05-15 | Krish S Krishnan | President and CEO | Sell | 3,842.00 | 57.43 | 220,639.14 | 1,932,620.00 | |